Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Yj Cerapeutics Inc. is currently navigating the patent prosecution process within the Biotechnology & Pharmaceuticals technology area. The company has 1 pending office action, which is assigned to 1 distinct art unit. This indicates a narrow technical focus for the current filing, likely centered on a specific biological or pharmaceutical innovation. By operating within 1 distinct art unit, the company can tailor its arguments to the specific examination standards and precedents of that technical group.
The prosecution is overseen by 1 distinct examiner, LEVIN, JOEL D. As the busiest examiner for this portfolio, he is responsible for the 1 pending office action currently active. This means the company's current patent prospects in this area depend on the review of this individual. Practitioners should analyze the past decisions and preferences of LEVIN, JOEL D to better anticipate the trajectory of the application. The presence of 1 pending office action suggests a highly targeted approach to intellectual property within the Biotechnology & Pharmaceuticals sector, requiring precise and well-supported technical responses to move the application toward allowance.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEVIN, JOEL D | 1 | 58.1% | +35.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18712101 | COMPOSITION FOR INDUCING TRANSDIFFERENTIATION AND STEM CELLS TREATED THEREWITH | LEVIN, JOEL D | — |
| Art Unit | Apps |
|---|---|
| 1633 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18712101 | COMPOSITION FOR INDUCING TRANSDIFFERENTIATION AND STEM CELLS TREATED THEREWITH | LEVIN, JOEL D | 1633 | §112 | Non-Final OA | — | Pending | May 21, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialYj Cerapeutics Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Joel D Levin has the most, with 1 of Yj Cerapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
